Pharmacovigilance and Its Importance for Primary Health Care Professionals

키워드

참고문헌 (42)

1. "The safety of medicines in public health programmes:pharmacovigilance, an essential tool" (2006)[URL]
2. Fornasier G, "An historical overview over Pharmacovigilance", Int J Clin Pharm, 40, pp.744~747 (2018)
3. McBride WG, "Thalidomide and congenital abnormalities", Lancet, 2, pp.P1358~ (1961)
4. "Making medicines safer for patients everywhere" (2021)[URL]
5. Watson S, "Reported adverse drug reactions in women and men : aggregated evidence from globally collected individual case reports during half a century", EClinicalMedicine, 17, pp.100188~ (2019)
6. Chandler RE, "The role of pharmacovigilance and ISoP during the global COVID-19 pandemic", Drug Saf, 43, pp.511~512 (2020)
7. Teo SP, "Sensible prescribing for older adults : illustrated cases", J Gerontol Geriatr, 65, pp.130~133 (2017)
8. Rosli N, "Reducing medication error and polypharmacy in older people", Asian J Gerontol Geriatr, 15, pp.86~90 (2020)
9. Kula M, "Geriatric nurses home visits : considerations for evaluating immobile older patients in the community", Pac J Med Sci, 21, pp.58~67 (2020)
10. Choo SZL, "Atypical femoral fracture secondary to long-term bisphosphonate use : a case report", Asian J Gerontol Geriatr, 15, pp.32~33 (2020)
11. Teo SP, "Denosumab for the treatment of osteoporosis", Aging Pathobiol Ther, 2, pp.168~170 (2020)
12. "Adverse drug reactions, part 1 - adverse drug reactions and medicines safety" (2021)[URL]
13. Rohilla A, "Pharmacovigilance : needs and objectives", J Adv Pharm Educ Res, 2, pp.201~205 (2012)
14. Tsintis P, "CIOMS and ICH initiatives in pharmacovigilance and risk management : overview and implications", Drug Saf, 27, pp.509~517 (2004)
15. Faich GA, "International reporting on adverse drug reactions : the CIOMS project : CIOMS ADR working group", Int J Clin Pharmacol Ther Toxicol, 28, pp.133~138 (1990)
16. Behera SK, "Comparison of different methods for causality assessment of adverse drug reactions", Int J Clin Pharm, 40, pp.903~910 (2018)
17. Rehan HS, "Causality assessment of spontaneously reported adverse drug events : comparison of WHO-UMC criteria and Naranjo probability scale", Int J Risk Saf Med, 19, pp.223~227 (2007)
18. Warner MR, "Implementing benefit-risk assessment for the periodic benefit-risk evaluation report", Ther Innov Regul Sci, 50, pp.342~346 (2016)
19. Arlett P, "Periodic benefit-risk evaluation report : a European Union regulatory perspective", Pharm Med, 28, pp.309~315 (2014)
20. Leong J, "Is there a need for a universal benefit-risk assessment framework for medicines? : regulatory and industry perspectives", Pharmacoepidemiol Drug Saf, 22, pp.1004~1012 (2013)
21. Piening S, "Healthcare professionals’ self-reported experiences and preferences related to direct healthcare professional communications : a survey conducted in the Netherlands", Drug Saf, 35, pp.1061~1072 (2012)
22. Weatherburn CJ, "Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes : systematic review, time series analysis and meta-analysis", Br J Clin Pharmacol, 86, pp.698~710 (2020)
23. Kwa M, "Adverse events reported to the US food and drug administration for cosmetics and personal care products", JAMA Intern Med, 177, pp.1202~1204 (2017)
24. Patel NM, "A pharmacovigilance study of adverse drug reactions reported for cardiovascular disease medications approved between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System(FAERS)database", Cardiovasc Drugs Ther, 36, pp.309~322 (2022)
25. Goedecke T, "Measuring the impact of medicines regulatory interventions : systematic review and methodological considerations", Br J Clin Pharmacol, 84, pp.419~433 (2018)
26. Tan SY, "Ciprofloxacin-associated seizures and acute kidney injury : a case report", Asian J Gerontol Geriatr, 16, pp.54~55 (2021)
27. Gerard A, "“Off-label” use of hydroxychloroquine, azithromycin, lopinavirritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French network of Pharmacovigilance centers", Therapie, 75, pp.371~379 (2020)
28. Nielsen PB, "Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage", Stroke, 50, pp.939~946 (2019)
29. Maure CG, "The global vaccine safety initiative : enhancing vaccine pharmacovigilance capacity at country level", Bull World Health Organ, 92, pp.695~696 (2014)
30. Teo SP, "Review of COVID-19 mRNA vaccines : BNT162b2 and mRNA-1273", J Pharm Pract (2021)[DOI]
31. Shyh Poh Teo, "Review of COVID-19 Vaccines and Their Evidence in Older Adults", Annals of geriatric medicine and research, 25(1), pp.4~9 (2021), 대한노인병학회[DOI]
32. Heininger U, "Guide to active vaccine safety surveillance: report of CIOMS working group on vaccine safety: executive summary", Vaccine, 35, pp.3917~3921 (2017)
33. Bihan K, "Uses of pharmacovigilance databases : an overview", Therapie, 75, pp.591~598 (2020)
34. Wiktorowicz M, "Pharmacovigilance in Europe and North America : divergent approaches", Soc Sci Med, 75, pp.165~170 (2012)
35. Biswas P, "Pharmacovigilance in Asia", J Pharmacol Pharmacother, 4(Suppl 1), pp.S7~S19 (2013)
36. Okechukwu RC, "Awareness, attitude, and practice of pharmacovigilance among health care professionals in Nigeria : survey in a teaching hospital", Int J Hosp Res, 2, pp.99~108 (2013)
37. Schutte T, "Pharmacovigilance skills, knowledge and attitudes in our future doctors : a nationwide study in the Netherlands", Basic Clin Pharmacol Toxicol, 120, pp.475~481 (2017)
38. Edwards B, "Defining the competencies of those conducting pharmacovigilance", Pharmacoepidemiol Drug Saf, 15, pp.193~198 (2006)
39. Reumerman M, "Urgent need to modernize pharmacovigilance education in healthcare curricula : review of the literature", Eur J Clin Pharmacol, 74, pp.1235~1248 (2018)
40. "Core competencies for drug safety/pharmacovigilance professionals" (2011)[URL]
41. Kshirsagar NA, "Consideration of the desirable features and possible forms of practical indicators of the performance of pharmacovigilance centres", Int J Risk Saf Med, 22, pp.59~66 (2010)
42. Brown P, "‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance : establishing a conceptual and methodological framework", Eur J Clin Pharmacol, 75, pp.1181~1192 (2019)

관련 논문AI추천